Defective Pharmaceuticals and Indeterminate Tortfeasors: A German Law Perspective on DES-Daughters Scenarios by Thiede, Thomas
www.ssoar.info
Defective Pharmaceuticals and Indeterminate
Tortfeasors: A German Law Perspective on DES-
Daughters Scenarios
Thiede, Thomas
Veröffentlichungsversion / Published Version
Zeitschriftenartikel / journal article
Empfohlene Zitierung / Suggested Citation:
Thiede, T. (2013). Defective Pharmaceuticals and Indeterminate Tortfeasors: A German Law Perspective on
DES-Daughters Scenarios. European Review of Private Law (ERPL), 21(2), 617-623. https://nbn-resolving.org/
urn:nbn:de:0168-ssoar-50904-2
Nutzungsbedingungen:
Dieser Text wird unter einer CC BY-NC-ND Lizenz
(Namensnennung-Nicht-kommerziell-Keine Bearbeitung) zur
Verfügung gestellt. Nähere Auskünfte zu den CC-Lizenzen finden
Sie hier:
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.de
Terms of use:
This document is made available under a CC BY-NC-ND Licence
(Attribution-Non Comercial-NoDerivatives). For more Information
see:
https://creativecommons.org/licenses/by-nc-nd/4.0
E uropean Review ofPrivate  Law 2-2013 [617-624] © Kluwer Law In ternational BV. P rin ted  in  th e  G reat Britain.
Defective Pharmaceuticals and Indeterminate Tortfeasors: A 
German Law Perspective on DES-Daughters Scenarios
THOMAS THIEDE*
For centuries, pharmaceuticals in Germany were exclusively produced in 
small-scale pharmacies and had only to comply with the requirements set out in 
the pharmacy regulations. This picture changed in the 1950s and 1960s, when the 
manufacturing of pharmaceuticals by pharmacies shifted to mass production by 
the pharmaceutical industry. The German legislator responded to this shift by 
introducing the Arzneimittelgesetz (AMG) (Medicine Act),1 which operates as 
special legislation in the field of the industrial production of pharmaceuticals, in 
1961. The statute regulates all matters arising in the context of pharmaceutical 
production, including the requirement to register new drugs and wait for 
permission before distribution can begin. As a result of a revision in 1976, the 
statute also provides rules on no-fault liability in cases of personal injury caused 
by defective pharmaceuticals.2 According to sections 84 et seq. AMG, any 
pharmaceutical manufacturer that makes a defective pharmaceutical product (due 
to errors in research, development, or manufacturing) available on the market 
that causes death or personal injury following the correct administration of the 
product is liable. The manufacturer is also liable when the harm results from a 
lack of technical information or from a lack of correct directions for usage.
The bases for liability for pharmaceuticals are not limited to the AMG.3 In 
addition, several other possible claims will be considered. Firstly - and very 
seldom, as the AMG is lex specialis -  a claim based on the Gesetz über die Haftung
* THOMAS THIEDE, Dr. iur., LL.B., LL.M., Institute for European Tort Law, Austrian Academy 
of Sciences; Institute for Civil, Foreign and International Private Law, University of Graz; 
European Centre of Tort and Insurance Law (ECTIL). The author would like to express his 
sincere gratitude to Dipl.-Humanbiol., PhD student Juliane Tinter for her extensive advice in all 
aspects related to biochemical mechanisms of the drugs addressed in this paper.
1 BGBl. (Bundesgesetzblatt (Federal Law  Gazette)) I 1961, pp. 533 et seq.
2 On the legislative changes, see BT-Drucks (Bundestagsdrucksache (Official Records o f the 
Parliament)), 7th election period no. 5025, p. 65; 7th election period no. 3060, pp. 31 et seq., 60 
et seq.; and election period no. 5091, pp. 20 et seq., all online available via <http://druck 
sachen.bundestag.de/drucksachen/>; K. FEIDEN, Die Neuordnung des Arzneimittelrechts, GOVI, 
Frankfurt/Main 1978, p. 12; K.-J. HENNING, ‘Der Nachweis der Wirksamkeit von 
Arzneimitteln’, N JW  (Neue Juristische Wochenschrift) 1978, p. 1671, at 1672; N. JENKE, 
Haftung fü r  fehlerhafte Arzneimittel und Medizinprodukte, Springer, Heidelberg 2004, p. 23; G. 
SCHUBERT, ‘Zur Einführung: Arzneimittelrecht’, JuS (Juristische Schulung) 1983, pp. 748 et seq.
3 See sec. 91 Arzneimittelgesetz (AMG); for a full picture, see E. VON CAEMMERER, Reform der 
Gefährdungshaftung, Gesammelte Schriften III, Mohr Siebeck, Tübingen 1983, pp. 261 et seq.
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fü r  fehlerhafte Produkte (ProdHaftG) (Product Liability Act) could arise.4 
Secondly, section 823 paragraph 1 Bürgerliches Gesetzbuch (BGB) (Civil Code) 
stipulates liability for any person who, intentionally or negligently, unlawfully 
injures the life, body, and health of another person. The cornerstone of such 
fault-based liability is the lack of diligence of the manufacturers as they failed to 
develop and manufacture a product made available on the market or did not 
provide information or warning on usage of the pharmaceutical in the manner 
that could be expected from a reasonable manufacturer in the circumstances of 
the case.5 Thirdly, a claim for damages could be based on breach of a statute 
under section 823 paragraph 2 BGB with section 5 AMG as the relevant statute 
prohibiting the distribution of any questionable pharmaceutical product.6
Any of these claims require a causal link between the conduct of the 
defendant pharmaceutical manufacturer (the relevant ‘conduct’ here will be the 
placing of a defective pharmaceutical on the market) and the violation of the 
protected rights under section 84 AMG and section 823 BGB (i.e., life, health, 
and bodily integrity).7 In determining such causation a but-for test is applied, and 
its results are subsequently limited to those events where the conduct of the 
defendant was generally apt to cause the result that has ocurred and the injury 
sustained was within the scope of protection of the norm that was infringed.8 In 
the specific context of injuries caused by defective pharmaceuticals, German 
courts construed these combined criteria as a fourfold test. In the leading case 
regarding Thalidomide, it was generally accepted that proof of causation did not 
include evidence such as a clinical experiment or medically and 
epidemiologically-founded explanations of the mechanisms of Thalidomide and 
the injury sustained. For the court, epidemiological studies indicating a strong 
statistical correlation between the administering of Thalidomide and the 
Thalidomide-specific congenital malformations sufficed.9 In the later Impletol
4 Section 15 para. 1 Gesetz über die Haftung fü r  fehlerhafte Produkte (Product Liability Act) 
provides for the exclusive application of the AMG.
5 Bundesgerichtshof (BGH) (Federal Court of Justice) 26 Nov. 1968, BGHZ (Entscheidungen des 
Bundesgerichtshof in Zivilsachen) 51, 91 = N JW  1969, 269 (note U. DIEDERICHSEN); BGH 19 
Jun. 1973, N JW  1602; BGH 3 Jun. 1975, N JW  1975, 1827; C. VON BAR, Verkehrspflichten, 
Heymann, Köln 1980, pp. 52 et seq.; J. ESSER & H.-L. WEYERS, Schuldrecht, vol. II/2 , 8th edn,
C.F. Müller, Heidelberg 2000, sec. 55 II 3, V, and sec. 55a.
6 See BGH 26 Nov. 1969, BGHZ 51, 91 at 103.
7 See sec. 84 para. 1 sent. 1 AMG: ‘infolge der Anwendung eines Arzneimittels’ (as a result of the 
administration of a pharmaceutical); C. GRÜNEBERG, in Palandt, Bürgerliches Gesetzbuch, 72th 
edn, C.H. Beck, München 2013, Vorb v § 249, no. 24 et seq.
8 C. VON BAR, Gemeineuropäisches Deliktsrecht, vol. II, C.H. Beck, München 1999, no. 437; 
G. BRÜGGEMEIER, Haftungsrecht, Springer, Berlin/Heidelberg 2006, p. 28; C. VAN DAM, 
European Tort Law, OUP, Oxford 2006, pp. 286 et seq.; W.B. SCHÜNEMANN, ‘Kausalität in der 
Gefährdungshaftung’, N JW  1981, pp. 2796 et seq.
9 Landgericht (LG) (County Court) Aachen 18 Dec. 1970, JZ  (Juristenzeitung) 1971, pp. 507 et seq.
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case, where the claimant suffered death after taking the pharmaceutical, the 
Oberlandesgericht (OLG) (Higher Regional Court) Stuttgart approved this 
approach but added that two additional conditions have to be met. As it was 
unclear whether the claimant had died as a result of the usage of Impletol or 
simply suffered a heart attack, the court required evidence of any scientific 
knowledge or experience to prove such a link (analogous experiences) and, 
moreover, evidence that no alternative cause of the particular injury sustained 
existed.10 The final condition was provided by the OLG Celle in a case where the 
claimant suffered personal injury due to a rare precondition after being 
vaccinated against TBC. The court held that the plaintiff would have to prove not 
only the specific causal link in his case but also general causation, that is, 
evidence that the pharmaceutical product was generally apt to cause injury.11 As a 
result, the proof of such a causal link was one of the most difficult tasks a 
claimant (and his legal and medical counsel) could possibly embark on as it is 
good law that any compensation is awarded only when it is established to the 
practically certain personal conviction of the judge that all conditions of liability - 
including the causal link - are present; a significant degree of probability or an 
overwhelming likelihood does not suffice.12 In contrast, the claimant lacks 
specific medical, pharmacological, or epidemiological knowledge if this exists at 
all: for some pharmaceuticals, for instance in neuroleptics and antidepressants, 
the exact biochemical mechanisms of action are only partially understood.13 
Additionally, it seems rather odd to require evidence that there could have been 
no other possible cause of the injury.
In the wake of the scandal surrounding HIV-contaminated blood products, 
it became obvious that claimants were unable to prove the causal link between
10 Oberlandesgericht (OLG) Stuttgart 23 Feb. 1989, VersR (Zeitschrift fü r  Versicherungsrecht, 
Haftungs- und Schadensrecht) 1990, 631 et seq.; see also LG Traunstein, MedR (Medizinrecht)
1995, p. 241, at 242; BGH 24 Jan. 1989, BGHZ 106, 273 = VersR 1989, pp. 399 et seq.
11 OLG Celle 27 Jun. 1983, VersR 1983, pp. 1143 et seq.
12 See sec. 286 Zivilprozessordnung (ZPO) (Code of Civil Procedure), and for this standard, see
F. BIEN, ‘Schadensrechtliches Alles-oder-Nichts-Prinzip und Beweislastumkehr’, ERPL 
(European Review o f Private Law) 2008, pp. 1083, 1089; MünchKommZPO/H. PRÜTTING, § 
402 ZPO, 3rd edn, Beck, München 2008, no. 1; S. STEEL, ‘Exceptional Doctrines of Natural 
Causation’, 2 JETL (Journal o f  European Tort Law) 2011, p. 294, at 304; J. TAUPITZ, 
‘Proportionalhaftung zur Lösung von Kausalitätsproblemen’, in FS Canaris, Beck, München 
2007, p. 1231, at 1235; G. WAGNER, ‘Proportionalhaftung’, in FS Hirsch, de Gruyter, 
Berlin/Boston 2008, p. 453.
13 See E. MUTSCHLER, G. GEISSLINGER, H.K. KROEMER, P. RUTH & M. SCHÄFER- 
KORTING, Mutschler Arzneimittelwirkungen, 9th edn, Wissenschaftliche Verlagsgesellschaft, 
Stuttgart 2008, pp. 162, 173.
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their HIV-infection and the contaminated blood products14 as the products 
themselves were disposed; it was unclear which products were contaminated and, 
thus, who was the actual pharmaceutical manufacturer of the contaminated 
product. The German legislator reacted and implemented a presumption of a 
causal connection between the defective pharmaceutical and the injury sustained 
by the claimant in the circumstances of the individual case.15 The claimant will 
now have to submit information relating to the manufacturer, the dosage, and the 
composition of the pharmaceutical product, as well as medical studies indicating a 
causal link between the pharmaceutical and, generally, that the type of injury is 
caused by that defective product.16
That said, and with a view to diethylstilbestrol (DES)-daughters cases, it is 
arguable whether such relaxation of the burden of proof meets the injured 
claimant’s needs in cases of multiple, indeterminate tortfeasors. Both section 93 
AMG and section 830 BGB specify corresponding rules under which several 
defendants may be responsible for a single injury. The norms provide that 
potential tortfeasors are each responsible for the full damage and that the same 
applies where it is certain that one of a number of defendants caused the injury 
but it is impossible for the plaintiff to identify the defendant who did in fact 
commit the wrong.17 For the latter extension of liability of multiple tortfeasors, it 
is good law that some additional conditions must be fulfilled. First, each of the 
tortfeasors must have committed a tort with all the requirements necessary to 
establish liability (excluding the causal link) having been provided by the claimant 
in court.18 Second, there must be no doubt that one of the tortfeasors in fact
14 OLG Düsseldorf 22 Jun. 1995, N J W 1995, pp. 3060 et seq.; OLG Hamm 23 Oct. 1996, NJW-RR 
(Neue Juristische Wochenschrift-Rechtsprechungsreport) 1997, 217 et seq.; OLG Celle 12. Jun.
1996, VersR 1998, 1023 etseq.; BGH 30. Apr. 1991, N JW  1991, 1948 etseq.
15 See sec. 84 para. 2 AMG, implemented by the Zweites Gesetz zur Änderung schadensersatz­
rechtlicher Vorschriften, BGBl. I 2002, pp. 2674 et seq., available online at <http://www. 
bundesanzeiger-verlag.de/evidenzzentrale/>.
16 See H.-J. KULLMANN, ‘Erleichterung der Beweisführung aus § 84 AMG’, in FS Gerda Müller, 
Carl Heymanns, Köln 2009, p. 253, at 256.
17 For a comparative and historical analysis, see R. ZIMMERMANN & J. KLEINSCHMIDT, in B. 
Winiger, H. Koziol, B.A. Koch, R. Zimmermann (eds.), Digest o f  European Tort Law, vol 1: 
Essential Cases on Causation, 2007 6a/2, nos. 1 et seq.; U. MAGNUS, ‘Germany’, in I. Gilead, 
M.D. Green & B.A. Koch (eds.), Proportional Liability: Analytical and Comparative Perspectives 
(forthcoming).
18 BGH 24 Jan. 1984, BGHZ 89, 383, at 399 = N JW  1984, 1226, at 1230; Staudinger/C. 
EBERL-BORGES, § 830 BGB, Sellier/de Gruyter, Berlin/Boston 2008, no. 11; H.-J. 
KULLMANN, ‘Arzneimittelhaftung bei Blutpräparaten’, in R. Damm, D. Hart (eds.), Regulierung 
von Gesundheitsrisiken, Nomos, Baden-Baden 1993, p. 133, at 147; MünchKommBGB/G. 
WAGNER, § 830 BGB, 5th edn, Beck, München 2009, nos. 47 et seq.
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caused the harm in question;19 this will not be the case where it cannot be ruled 
out that the injury was caused by an ‘innocent’ source such as the natural 
development of the condition from an underlying illness of the claimant. Third, it 
must be unclear who, in the group of potential tortfeasors, actually caused the 
injury. Finally, each of the contributions of several tortfeasors must, on its own, 
have been sufficient to cause the injury.20 Particularly the first and second 
conditions may prove burdensome to most prospective claimants as they could 
have used comparable pharmaceutical products of different manufacturers or they 
simply do not know which of a number of possible pharmaceuticals in what 
dosage were administered to them.21 These problems are aggravated by the fact 
that any solidary liability will be rejected in all cases where one of the 
manufacturers can prove that his product was without defect.22 It is well accepted 
that whenever it is possible to identify a causal link, allowing for the attribution of 
a distinct part of the damage to a single tortfeasor, the principle of partial liability 
takes priority over the rule of solidary liability.23
Without a doubt, there is an intense debate among academics focusing on 
concepts such as market share liability and proportional liability in general.24 
Some suggest that the narrow limits of the above-mentioned solidary liability 
should be abandoned in favour of a wider scope of application of joint and several
19 BGH 24 Jan. 1984, BGHZ  89, 383, at 399 = N JW  1984, 1226; R. ZIMMERMANN & 
J. KLEINSCHMIDT, n. 17, 6a/2, no. 11.
20 Reichsgericht (RG) (Supreme Court of the German Reich) 30 Jun. 1904, RGZ (Entscheidungen 
des Reichsgerichts) 58, 357, 361; BGH 15 Dec. 1970, BGHZ 55, 86, at 92 et seq., 95; BGH 7 
Nov. 1978, BGHZ 72, 355, at 358; BGH 27 May 1987, BGHZ  101, 108 = N JW  1987, 2810; 
MünchKommBGB/G. WAGNER, n. 18, nos. 36 et seq.
21 See BGH 11 Jan. 1994, N JW  1994, 932, at 934; C. VON BAR, ‘Empfehlen sich gesetzgebrische 
Maßnahmen zur rechtlichen Bewältigung der Haftung für Massenschäden?’, in Gutachten zum 
62. Deutschen Juristentag (DJT), Beck, München 1998, pp. A 57 et seq.; C. EBERL-BORGES, 
‘§ 830 BGB und die Gefährdungshaftung’, 196 AcP (Archiv fü r  die civilistische Praxis) 1996, 
p. 491, at 536; MünchKommBGB/G. WAGNER, n. 18, nos. 56, 51.
22 BGH, 2 Feb. 1962, VersR 1962, 430; BGH 24 Jan. 1984, BGHZ 89, 383, at 399 = N JW  1984, 
1226, at 1230; Staudinger/C. EBERL-BORGES, n. 18, no. 115; E. REINELT, ‘Zur Haftung des 
Arzneimittelherstellers für die Übertragung von Viren durch Blutprodukte’, VersR 1990, p. 565, 
567; MünchKommBGB/G. WAGNER, n. 18, no. 47.
23 BGH 13 Feb. 1976, BGHZ 66, 70, at 75 et seq. = N JW  1976, 797, at 798 et seq.; BGH 26 Oct. 
1978, BGHZ  72, 289, at 297 et seq. = N JW  1979, 164, at 165 et seq.; BGH 27 May 1987, BGHZ 
101, 106, at 113 = VersR 1987, 1193, at 1194 = N JW  1987, 2810, at 2812; BGH 31 Jan. 1995, 
N JW  1995, 1286, at 1288; MünchKommBGB/G. WAGNER, n. 18, no. 44; G. WAGNER, 
‘Aggregation and Divisibility of Damage in Germany’, in K. Oliphant (ed.), Aggregation and  
Divisibility ofDamage, Springer, Wien/New York 2009, no. 59.
24 T. BODEWIG, ‘Probleme alternativer Kausalität bei Massenschäden’, 185 AcP  1985, p. 505, at 
548; G. WAGNER, ‘Schadensersatz - Zwecke, Inhalte, Grenzen’, in E. Lorenz (ed.), Karlsruher 
Forum 2006, Verlag Versicherungswirtschaft, Karlsruhe 2006, pp. 80 et seq., and reference in 
n. 12.
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liability.25 It is argued that the placing of the defective pharmaceutical on the 
market in itself suffices as basis for liability due to the increased risk of harm 
occurring.26 And indeed, no innocent manufacturer would be liable as in sum the 
total amount of liability remains the same.27 Accordingly, the manufacturer ought 
to be liable for the extent to which his actions exposed the victim to the risk of 
harm.28 In addition, it is fundamentally understood in German tort law that the 
main purpose of tort law is the (full) compensation of damage (restitutio in 
integrum).29 This objective would not be achieved where, in spite of the fact that 
all conditions of liability are met, a victim who is unable to satisfy the standard of 
proof as to whether it was the defendant’s pharmaceutical that caused the injury - 
despite the high probability - goes uncompensated. Furthermore, it is generally 
agreed that prevention is an additional aim of tort law since having to compensate 
is basically assumed to have some measure of deterrent effect.30 Any such 
deterrent effect must then surely fail if a manufacturer is not held liable for his 
undoubtedly defective product.
The courts and a majority of legal scholars have been unwilling to seriously 
take up any of these proposals: proportional liability is rejected as it contradicts 
the statutory framework of German tort law in equating the creation of a risk of 
injury with harm itself.31 Some argue, any extension of liability to potential 
tortfeasors would violate the most fundamental principle of German tort law: in 
contrast to, for example, French tort law,32 it is understood that any injured
25 J. BRAUN, ‘Haftung für Massenschäden’, N J W 1998, p. 2318, at 2330.
26 T. BODEWIG, n. 24, p. 523; J. BRAUN, n. 25, p. 2330; C. SEYFERT, Mass Toxic Torts,, 
Duncker & Humblot, Berlin 2004, pp. 238 et seq.; see also J. HAGER, ‘Die Kausalität bei 
Massenschäden’ in FS Canaris, fn. 12, p. 403, at 413.
27 T. BODEWIG, n. 24, pp. 528 et seq.; F. BYDLINSKI, ‘Aktuelle Streitfragen um die alternative 
Kausalität’, in FS Beitzke, de Gruyter, Berlin/New York 1979, p. 6, at 30. This is of course no 
solace to an individual manufacturer who was in fact not responsible for the injury sustained.
28 T. BODEWIG, n. 24, p. 548.
29 F. BYDLINSKI, System und Prinzipien des Privatrechts, Springer, Wien/New York 1996, pp. 187 
et seq.; H. KOZIOL, Grundfragen des Schadenersatzrechts, Jan Sramek Verlag, Wien 2010, pp. 
75 et seq.; U. MAGNUS, ‘Comparative Report’, in U. Magnus (ed.), Unification o f Tort Law: 
Damages, Springer, Wien/New York 2001, p. 185; MünchKommBGB/G. WAGNER, Vor § 823 
BGB, 5th edn, Beck, München 2009, nos. 38 et seq. , all with extensive further reference.
30 U. MAGNUS, ‘Comparative Report’, in U. Magnus (ed.), Unification o f Tort Law: Damages, 
Sp2001, p. 187; F. BYDLINSKI, System und Prinzipien, pp. 190 et seq.; M. FAURE, ‘Economic 
Analysis’, in B.A. Koch & H. Koziol (eds.), Unification o f Tort Law: Strict Liability, Springer, 
Wien/New York 2002, pp. 364 et seq.
31 G. MÜLLER, Bericht zum 66. DJT, vol. II/1 , Beck, München 2006, p. L 28; J. TAUPITZ, n. 12, 
pp. 1234 et seq.
32 C. QUEZEL-AMBRUNAZ, ‘Fault, Damage and the Equivalence Principle in French Law’, 1 JETL 
2012, pp. 21 et seq.
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person should have to bear his losses himself unless the injury is attributable to 
another person. Such imputation can, however, only operate if the tortfeasors are 
known and demonstrated to be such.33 Finally, attention was drawn to the 
legislator as the DES-daughters cases became known well before the last revision 
of both the AMG and the BGB. It is felt that a market share or proportional 
liability was rejected due to substantial problems in determining such share at a 
given time and the simple fact that some manufacturers no longer exist.34 Under 
present German law, the problem at hand may thus be understood not as the 
causal link between the pharmaceutical product and the injury sustained but the 
inability to determine the actual wrongdoer with certainty; in this latter case, 
however, the solidary liability mentioned above cannot apply.35
In conclusion, a claim in a DES-daughters scenario would most probably be 
denied in spite of recent reforms. However, as reality is the antithesis of 
expectation, any fears for the injured claimants may well be misplaced. Any 
difficulty with gathering evidence in the German Public Health Insurance system 
will be - unlike in the USA - less pressing as German doctors prescribe specific 
pharmaceuticals and pharmacies are only allowed to substitute them to a limited 
extent.36 Any information as regards prescription and substitution is documented 
and retained for a long period of time. Thus, any pharmaceutical manufacturer 
can be determined easily.37 Additionally, in specific cases (such as the 
Thalidomide and HIV cases, above), where the defendants could not be held liable 
for reasons such as those outlined here, manufacturers are subject to specific 
statutory schemes38 established by central government to provide financial help 
for victims of these defective pharmaceuticals. Finally, the widespread and 
long-standing availability of social insurance in Germany lightens the burden of 
people injured in such a scenario as discussed here; they will be able to recover 
pecuniary loss as normal via the machinery of social insurance with tort law being 
relegated to deal with non-pecuniary loss only.
33 E. DEUTSCH, ‘Das Arzneimittelrecht im Haftungssystem’, VersR 1979, p. 685, at 689; O. DE 
LOUSANOFF, ‘Market Share Liability’, R IW  (Recht der internationalen Wirtschaft) 1983, pp. 
151 et seq.; E. REINELT, n. 22, p. 567; H. STOLL, Haftungsfolgen im bürgerlichen Recht, C.F. 
Müller, Heidelberg 1999, p. 116; J. TAUPITZ, n. 12, p. 1235.
34 C. VON BAR, n. 21, p. 71; L. RÖCKRATH, Kausalität, Wahrscheinlichkeit und Haftung, Beck, 
München 2001, pp. 174 et seq.; Staudinger/C. EBERL-BORGES, n. 18, no. 111.
35 C. VON BAR, n. 21, p. 69; C. EBERL-BORGES, n. 21; G. MÜLLER, n. 31, L 28 etseq.
36 C.R. BARTRAM, Bericht zum 62. DJT, vol. II/1 , Beck, München 1998, pp. I 123 et seq.
37 C.R. BARTRAM, n. 36.
38 See Gesetz über die humanitäre Hilfe fü r  durch Blutprodukte HIV-infizierte Personen BGBl. I 
1995, p. 972; ‘Gesetz über die Errichtung einer Stiftung “Hilfswerk für behinderte Kinder”’ 
1971, BGBl. I 1971, p. 2018, available online <http://www.bundesanzeiger-verlag.de/evidenz 
zentrale/>.
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